Peter J. Mariani - 15 Jun 2026 Form 4 Insider Report for Cytosorbents Corp (CTSO)

Reporting relationship: Chief Financial Officer
Issuer ticker: CTSO
Reported as of: 15 Jun 2026
Net transaction value: +$44,000
SEC form: 4
Accepted by SEC: 16 Jun 2026, 07:00:14 UTC
Prior SEC filing: 08 Aug 2025
Source filing: View source filing
Reporting owner signature: /s/ Peter J. Mariani

Key filing fact

Peter J. Mariani filed Form 4 for Cytosorbents Corp (CTSO) on 16 Jun 2026.

Key facts

This page summarizes Peter J. Mariani's Form 4 filing for Cytosorbents Corp (CTSO).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 16 Jun 2026, 07:00.

Change

Previous filing in this sequence was filed on 08 Aug 2025.
Current net transaction value: +$44,000.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001222357 Primary reporting owner

MARIANI PETER J

Relationship: Chief Financial Officer
Address: C/O CYTOSORBENTS CORPORATION, 305 COLLEGE ROAD EAST, PRINCETON
Signature: /s/ Peter J. Mariani
Signature date: 16 Jun 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

CTSO transaction

Common Stock

Purchase

Transaction value: $44,000
Shares: +100,000
Change %: +19%
Price: $0.4400
Shares after: 638,113
Date: 15 Jun 2026
Ownership: Direct
Footnotes: F1, F2, F3, F4, F5

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 5 footnotes

Footnote F1

The transaction reported on this Form 4 reflects an open market purchase made by the Reporting Person. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.40 to $0.45, inclusive. The Reporting Person undertakes to provide to CytoSorbents Corporation (the "Issuer"), any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote (1) to this Form 4.

Footnote F2

Includes (a) 110,000 restricted stock units ("RSUs"), which will be settled into the Issuer's common stock, par value $0.001 per share (the "Common Stock"), upon vesting upon the earlier of (i) a "Change In Control" of the Issuer, as defined in the Reporting Person's employment agreement (the "Employment Agreement"), or (ii) the fourth anniversary from the date of grant, or August 14, 2028, subject to the Reporting Person's continued service as of the applicable vesting date;

Footnote F3

(continued from footnote 2) (b) 65,000 RSUs, of which 32,500 remain unvested as of the date hereof, and which shall vest as to one-half of the award on each of the first and second anniversaries of the date of grant, subject to the Reporting Person's continued service as of the applicable vesting date and will be settled into Common Stock upon vesting;

Footnote F4

(continued from footnote 3) (c) 175,000 RSUs, which will be settled into Common Stock upon a "Change In Control" of the Issuer, as defined in the Reporting Person's Employment Agreement, subject to the Reporting Person's continued service as of the applicable vesting date; (d) 71,500 RSUs, which shall vest as to one-half of the award on each of the first and second anniversaries of the date of grant, subject to the Reporting Person's continued service as of the applicable vesting date and will be settled into Common Stock upon vesting; and

Footnote F5

(continued from footnote 4) (e) 216,613 shares of Common Stock owned by the Reporting Person.